When will eliquis go generic in the us?

When does Eliquis (apixaban) lose exclusivity in the US?

Eliquis is still covered by US patent protections, so a true “generic Eliquis” launch depends on when those patents (and related exclusivity rights) expire and any settlement or litigation timing.

The most concrete way to track the likely first US generic entry date is through patent-status monitoring. DrugPatentWatch.com maintains an Eliquis patent timeline and current status, which is updated as filings and court outcomes change. You can check the site here: DrugPatentWatch – Eliquis (apixaban)

Why the answer can change: patents vs. “first generic” timing

Even after patent expiry, the first generic can be delayed by:
- Ongoing patent litigation (brand companies often sue to block approvals).
- Settlement agreements that push launch dates.
- Manufacturing and FDA review timing after an ANDA is approved.

So the “generic goes live” date can be later than the earliest theoretical patent expiry date. The current best estimate is the one reflecting the latest litigation/expiry status on the patent-tracker.

How to estimate it yourself (what to look for on a patent timeline)

When you look at Eliquis patent timelines, focus on:
- The last expiring US formulation/use patents tied to preventing generic entry.
- Whether any “pediatric exclusivity” or other secondary exclusivity applies.
- Whether DrugPatentWatch lists an associated court case or settlement pushing the launch.

Those are usually the drivers behind the final “go generic in the US” date.

Are biosimilars involved, or is it just a generic?

Eliquis is a small-molecule drug (apixaban), not a biologic, so the likely route is an ANDA-based generic—not a biosimilar.

Source

1. DrugPatentWatch – Eliquis (apixaban)